HLA-mismatched microtransplantation

HLA-mismatched microtransplantation (MST) is an investigational cellular immunotherapy that involves the infusion of HLA-mismatched donor hematopoietic stem cells (typically from peripheral blood) following chemotherapy, notably without the use of post-transplant immunosuppressive drugs. Developed and evaluated by the Institut Paoli-Calmettes, this approach aims to induce a state of transient donor micro-chimerism. This micro-chimerism facilitates a potent graft-versus-leukemia (GVL) effect, where the donor's immune cells attack the recipient's malignant cells, while avoiding the severe graft-versus-host disease (GVHD) typically associated with mismatched allogeneic transplants. MST is primarily targeted at older or medically unfit patients with myeloid malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), who are considered ineligible for conventional allogeneic hematopoietic stem cell transplantation.

Other names

MicrotransplantationMSTHLA-mismatched Microtransplantation Without Immunosuppressive Treatment